First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2012-01-25 10:22:42Open Document File Size: 350,83 KBShare Result on FacebookCityGadolinium / /CompanyBayer HealthCare Pharmaceuticals Inc. / /EventFDA Phase / Product Issues / /IndustryTermdiagnostic magnetic resonance imaging / physiological saline solution / yellow solution / contrast media / rubber stopper / chemical / imaging / /MedicalConditionNephrogenic Systemic Fibrosis Gadolinium-based contrast agents / loss of consciousness / chronic / severe kidney disease / local irritation / hypertension / severe kidney disease / bronchospasm / bronchial asthma / chest pain / laryngeal edema / disease / flushing / headache / kidney disease / moderate irritation / dysgeusia / shock / Carcinogenesis / Acute kidney injury / dysfunction / Chronic / convulsion / nausea / diabetes / allergic disorders / hyperhidrosis / chronic hypertension / conjunctivitis / injury / diabetes mellitus / urticaria / angioedema / tachycardia / Hypersensitivity / anaphylactic reactions / inflammatory cells / infection / Cardiac arrest / cough / Anaphylactoid/anaphylactic reactions / Pruritus / NEPHROGENIC SYSTEMIC FIBROSIS / fibrosis / hypotension / /MedicalTreatmentcatheter / resuscitation / hemodialysis / cannula / drug therapy / surgery / dialysis / /OrganizationBefore Gadavist administration / National Science Foundation / DOSAGE AND ADMINISTRATION / FDA / Gadavist administration / / /PositionGeneral / /ProductGadavist injection / VOLUME OF GADAVIST INJECTION / Palm Pre Plus Smartphone / elimination / L / Gadavist / /TechnologyPharmacokinetics / MRI system / magnetic resonance imaging / Pharmacodynamics / MRI / dialysis / /URLwww.fda.gov/medwatch / /SocialTag |